Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system
BackgroundLoss of vascular integrity is a common comorbidity of neurodegenerative diseases of the central nervous system (CNS). Compromised blood flow to the brain and excessive vascular remodeling is evident in chronic systemic cardiovascular diseases such as atherosclerosis, driving neurodegenerat...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2025.1569347/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849728049002577920 |
|---|---|
| author | Olivia L. Bossardet Joseph M. Holden Brian J. Del Buono Eric Schlumpf Lauren K. Wareham David J. Calkins |
| author_facet | Olivia L. Bossardet Joseph M. Holden Brian J. Del Buono Eric Schlumpf Lauren K. Wareham David J. Calkins |
| author_sort | Olivia L. Bossardet |
| collection | DOAJ |
| description | BackgroundLoss of vascular integrity is a common comorbidity of neurodegenerative diseases of the central nervous system (CNS). Compromised blood flow to the brain and excessive vascular remodeling is evident in chronic systemic cardiovascular diseases such as atherosclerosis, driving neurodegeneration and subsequent cognitive decline. Vascular remodeling occurs in response to changes in the microenvironment, with the extracellular matrix (ECM) as a major component. Collagens within the ECM and vascular basement membrane are integral to endothelial cell (EC) function and maintenance of the blood-brain barrier. Disruption of the ECM and breakdown of collagen with disease may lead to vascular dysfunction and neurodegeneration.MethodsWe induced hyperglycemia in ApoE-deficient (ApoE−/−) mice by intraperitoneal injection of streptozocin (STZ; 50 mg/Kg) for 5 days and accelerated diabetic atherosclerotic disease through a high fat diet (HFD). Over a 12 weeks period, mice received weekly intravenous treatment of collagen mimetic peptide (CMP) or vehicle (phosphate buffered saline) to assess efficacy in promoting vascular integrity in central brain structures.ResultsFollowing the STZ/HFD regimen, diabetic atherosclerotic ApoE−/− mice treated with CMP exhibited increased vascular integrity compared to vehicle in the cortex and in the CA1 and dentate gyrus regions of the hippocampus, as assed by higher levels of the endothelial cell adhesion glycoprotein CD31 and intravascular collagen IV, increased vascular area, and diminished leakage. Interestingly, in hippocampus, astrocytes were closer in proximity to vessels despite being less numerous in the CMP group.ConclusionCollagen integrity is important for maintaining cerebrovascular architecture in disease. Application of CMP which intercalates with and repairs damaged collagen may have therapeutic use in neurodegenerative diseases by preserving vasculature structure and promoting blood-brain barrier integrity. These findings underscore the need to further explore the role of collagen repair as a novel therapeutic for diseases of the brain involving vascular degradation. |
| format | Article |
| id | doaj-art-8067481db8114e2baa08f4db13a606b5 |
| institution | DOAJ |
| issn | 1662-453X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj-art-8067481db8114e2baa08f4db13a606b52025-08-20T03:09:41ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2025-05-011910.3389/fnins.2025.15693471569347Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous systemOlivia L. Bossardet0Joseph M. Holden1Brian J. Del Buono2Eric Schlumpf3Lauren K. Wareham4David J. Calkins5Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United StatesDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United StatesSailfish Therapeutics, LLC, Stuart, FL, United StatesSailfish Therapeutics, LLC, Stuart, FL, United StatesDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United StatesDepartment of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United StatesBackgroundLoss of vascular integrity is a common comorbidity of neurodegenerative diseases of the central nervous system (CNS). Compromised blood flow to the brain and excessive vascular remodeling is evident in chronic systemic cardiovascular diseases such as atherosclerosis, driving neurodegeneration and subsequent cognitive decline. Vascular remodeling occurs in response to changes in the microenvironment, with the extracellular matrix (ECM) as a major component. Collagens within the ECM and vascular basement membrane are integral to endothelial cell (EC) function and maintenance of the blood-brain barrier. Disruption of the ECM and breakdown of collagen with disease may lead to vascular dysfunction and neurodegeneration.MethodsWe induced hyperglycemia in ApoE-deficient (ApoE−/−) mice by intraperitoneal injection of streptozocin (STZ; 50 mg/Kg) for 5 days and accelerated diabetic atherosclerotic disease through a high fat diet (HFD). Over a 12 weeks period, mice received weekly intravenous treatment of collagen mimetic peptide (CMP) or vehicle (phosphate buffered saline) to assess efficacy in promoting vascular integrity in central brain structures.ResultsFollowing the STZ/HFD regimen, diabetic atherosclerotic ApoE−/− mice treated with CMP exhibited increased vascular integrity compared to vehicle in the cortex and in the CA1 and dentate gyrus regions of the hippocampus, as assed by higher levels of the endothelial cell adhesion glycoprotein CD31 and intravascular collagen IV, increased vascular area, and diminished leakage. Interestingly, in hippocampus, astrocytes were closer in proximity to vessels despite being less numerous in the CMP group.ConclusionCollagen integrity is important for maintaining cerebrovascular architecture in disease. Application of CMP which intercalates with and repairs damaged collagen may have therapeutic use in neurodegenerative diseases by preserving vasculature structure and promoting blood-brain barrier integrity. These findings underscore the need to further explore the role of collagen repair as a novel therapeutic for diseases of the brain involving vascular degradation.https://www.frontiersin.org/articles/10.3389/fnins.2025.1569347/fullvascular dysfunctioncerebrovascular diseaseneurodegenerationcollagencollagen mimetic peptidesextracellular matrix |
| spellingShingle | Olivia L. Bossardet Joseph M. Holden Brian J. Del Buono Eric Schlumpf Lauren K. Wareham David J. Calkins Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system Frontiers in Neuroscience vascular dysfunction cerebrovascular disease neurodegeneration collagen collagen mimetic peptides extracellular matrix |
| title | Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system |
| title_full | Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system |
| title_fullStr | Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system |
| title_full_unstemmed | Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system |
| title_short | Collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system |
| title_sort | collagen mimetic peptides as novel therapeutics for vascular disease in the central nervous system |
| topic | vascular dysfunction cerebrovascular disease neurodegeneration collagen collagen mimetic peptides extracellular matrix |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2025.1569347/full |
| work_keys_str_mv | AT olivialbossardet collagenmimeticpeptidesasnoveltherapeuticsforvasculardiseaseinthecentralnervoussystem AT josephmholden collagenmimeticpeptidesasnoveltherapeuticsforvasculardiseaseinthecentralnervoussystem AT brianjdelbuono collagenmimeticpeptidesasnoveltherapeuticsforvasculardiseaseinthecentralnervoussystem AT ericschlumpf collagenmimeticpeptidesasnoveltherapeuticsforvasculardiseaseinthecentralnervoussystem AT laurenkwareham collagenmimeticpeptidesasnoveltherapeuticsforvasculardiseaseinthecentralnervoussystem AT davidjcalkins collagenmimeticpeptidesasnoveltherapeuticsforvasculardiseaseinthecentralnervoussystem |